Regenxbio (RGNX) Provides Update on RGX-181 and RGX-381 Programs streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX) today announced a comprehensive program update to outline its progress and development plans for RGX-181 and.
/PRNewswire/ REGENXBIO Inc. (Nasdaq: RGNX) today announced it has completed dosing in the expanded Cohort 2 of the Phase I/II trial of RGX-111 for the.
/PRNewswire/ Research and development is still focused on trying to help understand the acute infection 9itself and the effects of long COVID as well. As.
RGX-314 continues to be well tolerated in 50 patients from Cohorts 1-3 with no drug-related serious adverse events Patients treated with RGX-314 in Cohorts 1-3.